FDA panel to review Gardasil for HPV-related anal disease
This article was originally published in Scrip
Executive Summary
The US FDA's vaccines and related products advisory committee will meet on 17 November to discuss the effectiveness of vaccinating males and females with Merck & Co's HPV vaccine Gardasil to prevent anal dysplasia and anal cancer, filed through a supplemental BLA.